Illustrative image – not actual.Designed to meet global regulatory standards, including those of the US FDA, European Medicines Agency (EMA), and other leading health authorities, the facility is now fully operational, with GMP qualification activities currently in progress.
The development represents a major milestone in Shilpa Medicare’s evolution and builds upon more than 25 years of expertise in manufacturing highly potent active pharmaceutical ingredients (HPAPIs). The new facility strengthens the company’s position in advanced biopharmaceutical manufacturing by providing integrated, end-to-end ADC drug substance development and production capabilities. These include payload synthesis, linker development and manufacturing, monoclonal antibody production, ADC conjugation, and GMP-scale purification. ADC manufacturing requires specialised containment systems, advanced conjugation technologies, and stringent biologic purification processes, all of which are incorporated within the facility.
With this commissioning, the company becomes one of the few firms in India capable of offering fully integrated ADC drug substance manufacturing services. The facility enhances the company’s ability to serve global pharmaceutical and biotechnology firms as a cost-competitive Contract Development and Manufacturing Organization (CDMO).
